Does the media prefer ADMA or ANIP?

In the previous week, ADMA Biologics had 8 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for ADMA Biologics and 1 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.24 beat ADMA Biologics' score of 0.26 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ANIP or ANVS?

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 1 articles in the media. ANI Pharmaceuticals' average media sentiment score of 1.24 beat Annovis Bio's score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, QGEN or ANIP?

Qiagen has higher revenue and earnings than ANI Pharmaceuticals. Qiagen is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.70 $424.88M $1.91 19.64 ANI Pharmaceuticals $883.37M 2.04 $78.34M $3.95 20.05

Does the media prefer QGEN or ANIP?

In the previous week, Qiagen had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 6 mentions for Qiagen and 1 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.24 beat Qiagen's score of -0.43 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IMVT or ANIP?

In the previous week, Immunovant had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 6 mentions for Immunovant and 1 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.24 beat Immunovant's score of 0.43 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ANIP or PCVX?

In the previous week, Vaxcyte had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 5 mentions for Vaxcyte and 1 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.24 beat Vaxcyte's score of 0.21 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ANI Pharmaceuticals (ANIP) Competitors

$79.20 +3.97 (+5.28%)

Closing price 04:00 PM Eastern

Extended Trading

$79.17 -0.03 (-0.04%)

As of 04:10 PM Eastern

Compare

ANIP vs. ADMA, ANVS, QGEN, IMVT, and PCVX

Should you buy ANI Pharmaceuticals stock or one of its competitors? MarketBeat compares ANI Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Qiagen (QGEN), Immunovant (IMVT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

How does ANI Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ADMA Biologics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

ADMA Biologics currently has a consensus price target of $19.00, indicating a potential upside of 138.54%. ANI Pharmaceuticals has a consensus price target of $107.33, indicating a potential upside of 35.52%. Given ADMA Biologics' higher probable upside, equities research analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, ADMA Biologics had 8 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for ADMA Biologics and 1 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.24 beat ADMA Biologics' score of 0.26 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has a net margin of 32.43% compared to ANI Pharmaceuticals' net margin of 9.98%. ADMA Biologics' return on equity of 39.98% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

ADMA Biologics has higher earnings, but lower revenue than ANI Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.62	$146.93M	$0.68	11.71
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05

Summary

ADMA Biologics and ANI Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

ANI Pharmaceuticals (NASDAQ:ANIP) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

ANI Pharmaceuticals has a net margin of 9.98% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Annovis Bio	N/A	-318.08%	-215.47%

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

ANI Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

ANI Pharmaceuticals presently has a consensus target price of $107.33, indicating a potential upside of 35.52%. Annovis Bio has a consensus target price of $13.50, indicating a potential upside of 583.54%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 1 articles in the media. ANI Pharmaceuticals' average media sentiment score of 1.24 beat Annovis Bio's score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ANI Pharmaceuticals beats Annovis Bio on 11 of the 14 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Qiagen?

Qiagen (NYSE:QGEN) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Qiagen had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 6 mentions for Qiagen and 1 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.24 beat Qiagen's score of -0.43 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen currently has a consensus price target of $44.98, indicating a potential upside of 19.92%. ANI Pharmaceuticals has a consensus price target of $107.33, indicating a potential upside of 35.52%. Given ANI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63

Qiagen has a net margin of 19.16% compared to ANI Pharmaceuticals' net margin of 9.98%. ANI Pharmaceuticals' return on equity of 27.51% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

70.0% of Qiagen shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Qiagen has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Qiagen has higher revenue and earnings than ANI Pharmaceuticals. Qiagen is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.70	$424.88M	$1.91	19.64
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05

Summary

ANI Pharmaceuticals beats Qiagen on 9 of the 17 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

In the previous week, Immunovant had 5 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 6 mentions for Immunovant and 1 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.24 beat Immunovant's score of 0.43 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05

ANI Pharmaceuticals has a net margin of 9.98% compared to Immunovant's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

47.1% of Immunovant shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Immunovant has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Immunovant currently has a consensus price target of $37.33, indicating a potential upside of 14.27%. ANI Pharmaceuticals has a consensus price target of $107.33, indicating a potential upside of 35.52%. Given ANI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

ANI Pharmaceuticals beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Vaxcyte?

ANI Pharmaceuticals (NASDAQ:ANIP) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

ANI Pharmaceuticals has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

In the previous week, Vaxcyte had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 5 mentions for Vaxcyte and 1 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.24 beat Vaxcyte's score of 0.21 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals has a net margin of 9.98% compared to Vaxcyte's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.51% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Vaxcyte	N/A	-32.51%	-29.51%

ANI Pharmaceuticals currently has a consensus target price of $107.33, suggesting a potential upside of 35.52%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 76.37%. Given Vaxcyte's higher possible upside, analysts clearly believe Vaxcyte is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

ANI Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.04	$78.34M	$3.95	20.05
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Summary

ANI Pharmaceuticals beats Vaxcyte on 9 of the 14 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIP vs. The Competition

Export

Metric	ANI Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.80B	$3.35B	$6.44B	$12.47B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	20.05	18.72	23.87	24.40
Price / Sales	2.04	320.32	521.86	117.01
Price / Cash	7.51	110.40	41.27	57.13
Price / Book	3.30	6.80	9.99	6.73
Net Income	$78.34M	$24.09M	$3.56B	$337.03M
7 Day Performance	-2.35%	-2.48%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	30.11%	48.95%	28.77%	34.24%

ANI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIP ANI Pharmaceuticals	3.8034 of 5 stars	$79.20 +5.3%	$107.33 +35.5%	+22.0%	$1.80B	$883.37M	20.05	600	Positive News Analyst Forecast
ADMA ADMA Biologics	4.8116 of 5 stars	$8.24 flat	$19.00 +130.6%	-62.1%	$1.91B	$510.17M	12.12	530
ANVS Annovis Bio	2.1439 of 5 stars	$2.25 +0.7%	$13.50 +501.3%	-28.7%	$77.26M	N/A	N/A	3	High Trading Volume
QGEN Qiagen	3.9843 of 5 stars	$35.23 +0.2%	$44.98 +27.7%	-23.5%	$7.25B	$2.09B	18.40	5,654
IMVT Immunovant	2.1313 of 5 stars	$34.15 flat	$35.33 +3.5%	+101.7%	$7.01B	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIP) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, QGEN, IMVT, and PCVX

How does ANI Pharmaceuticals compare to ADMA Biologics?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Summary

How does ANI Pharmaceuticals compare to Qiagen?

Summary

How does ANI Pharmaceuticals compare to Immunovant?

Summary

How does ANI Pharmaceuticals compare to Vaxcyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, QGEN, IMVT, and PCVX

How does ANI Pharmaceuticals compare to ADMA Biologics?

Do institutionals and insiders believe in ADMA or ANIP?

Which has more volatility & risk, ADMA or ANIP?

Do analysts recommend ADMA or ANIP?

Does the media prefer ADMA or ANIP?

Is ADMA or ANIP more profitable?

Which has stronger valuation and earnings, ADMA or ANIP?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Is ANIP or ANVS more profitable?

Do institutionals & insiders hold more shares of ANIP or ANVS?

Which has preferable valuation & earnings, ANIP or ANVS?

Which has more volatility & risk, ANIP or ANVS?

Do analysts rate ANIP or ANVS?

Does the media favor ANIP or ANVS?

Summary

How does ANI Pharmaceuticals compare to Qiagen?

Does the media prefer QGEN or ANIP?

Do analysts rate QGEN or ANIP?

Is QGEN or ANIP more profitable?

Do institutionals & insiders believe in QGEN or ANIP?

Which has more risk & volatility, QGEN or ANIP?

Which has stronger valuation & earnings, QGEN or ANIP?

Summary

How does ANI Pharmaceuticals compare to Immunovant?

Does the media prefer IMVT or ANIP?

Which has stronger earnings & valuation, IMVT or ANIP?

Is IMVT or ANIP more profitable?

Do institutionals and insiders believe in IMVT or ANIP?

Which has more risk & volatility, IMVT or ANIP?

Do analysts prefer IMVT or ANIP?

Summary

How does ANI Pharmaceuticals compare to Vaxcyte?

Which has more volatility and risk, ANIP or PCVX?

Does the media favor ANIP or PCVX?

Do insiders and institutionals hold more shares of ANIP or PCVX?

Is ANIP or PCVX more profitable?

Do analysts recommend ANIP or PCVX?

Which has better earnings & valuation, ANIP or PCVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools